<DOC>
	<DOCNO>NCT02184572</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety GSK Biologicals ' trivalent MMR ( Priorix® ) , compare Merck 's MMR vaccine ( M-M-R®II ) , approve use US healthy child 12 15 month age .</brief_summary>
	<brief_title>Safety Immunogenicity Study GlaxoSmithKline ( GSK ) Biologicals ' Measles , Mumps Rubella ( MMR ) Vaccine ( 209762 ) Compared Merck &amp; Co. , Inc. 's MMR Vaccine Healthy Children 12 15 Months Age</brief_title>
	<detailed_description>This study evaluate safety GSK 's trivalent MMR vaccine ( referred INV_MMR vaccine ) potency use define maximum release limit Inv_MMR comparison US standard care ( M-M-R II/ M-M-R VaxPro vaccine refer Com_MMR vaccine ) . In order obtain representative data comparator vaccine , Com_MMR use study consist two lot designate Com_MMR_L1 Com_MMR_L2 . Throughout study Com_MMR_L1 Com_MMR_L2 analyze pooled lot . This study intend support licensure GSK 's MMR vaccine US . All child receive Varivax Havrix vaccine , concomitantly MMR contain vaccine 12 15 month age . Prevnar 13 administer US child . At end study , GSK provide second dose Havrix and/or varicella vaccine participant enrol select non-US country local health department routinely provide hepatitis A varicella vaccination . The second dose Havrix varicella vaccine part study procedure .</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Mumps</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female child 12 15 month age ( e.g. , 1 year birthday day age 16 month ) time vaccination . Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply , requirement protocol . Written inform consent obtain parent ( ) /LAR ( ) child . Child stable health determine investigator 's clinical examination assessment child 's medical history . For US child : child receive routine vaccination per ACIP recommendation prior study entry : completion hepatitis B rotavirus series completion primary series diphtheria , tetanus , pertussis , poliovirus , Haemophilus influenzae type b ( Hib ) pneumococcal vaccine . The 3dose infant series Prevnar 13 complete least 60 day prior study vaccination . Child care . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) period start 30 day day study vaccination ( i.e. , 30 day prior Day 0 ) plan use entire study period . Concurrently participate another clinical study , child expose investigational noninvestigational product ( pharmaceutical product device ) . Chronic administration ( define 14 consecutive day ) immunosuppressant , immunemodifying drug period start 180 day prior study vaccination Visit 1 plan administration immunosuppressive immunemodifying drug entire study . For corticosteroid , mean prednisone ≥0.5 mg/kg/day equivalent . Inhaled topical steroid allow . Planned administration/ administration vaccine foreseen study protocol period start 30 day prior day study vaccination Visit 1 end Visit 2 . Please Note : Inactivated influenza ( Flu ) vaccine monovalent Haemophilus influenzae type b conjugate vaccine ( Hib ) vaccine may give time , include day study vaccination ( Flu Hib vaccine must administer different location study vaccine/s ) . Any age appropriate vaccine may give start Visit 2 anytime thereafter . Administration immunoglobulins and/or blood product period start 180 day study vaccination Visit 1 plan administration date vaccination immunogenicity evaluation Visit 2 . History measles , mumps , rubella , varicella/zoster and/or hepatitis A disease . Known exposure measles , mumps , rubella and/or varicella/zoster period start within 30 day prior first study vaccination . Previous vaccination measles , mumps , rubella , hepatitis A and/or varicella virus . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . Blood dyscrasia , leukemia , lymphomas type , malignant neoplasm affect bone marrow lymphatic system . A family history congenital hereditary immunodeficiency . History allergic disease reaction likely exacerbate component vaccine , include hypersensitivity neomycin , latex gelatin . Acute disease time enrollment . ( Acute disease define presence moderate severe illness without fever ) . Fever define temperature ≥38.0°C/100.4°F age appropriate route . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without fever . Active untreated tuberculosis base medical history . Any condition , opinion investigator , prevents child participate study . For US child : child previously receive fourth dose PCV13 vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Rubella</keyword>
	<keyword>Healthy child</keyword>
	<keyword>Measles</keyword>
	<keyword>Safety</keyword>
	<keyword>Mumps</keyword>
	<keyword>12 15 month</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>